<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37540896</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-1331</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>12</Issue><PubDate><Year>2023</Year><Month>Dec</Month></PubDate></JournalIssue><Title>European journal of neurology</Title><ISOAbbreviation>Eur J Neurol</ISOAbbreviation></Journal><ArticleTitle>What do we mean by long COVID? A scoping review of the cognitive sequelae of SARS-CoV-2 infection.</ArticleTitle><Pagination><StartPage>3968</StartPage><EndPage>3978</EndPage><MedlinePgn>3968-3978</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ene.16027</ELocationID><Abstract><AbstractText Label="BACKGROUND AND PURPOSE">Many COVID-19 patients report persistent symptoms, including cognitive disturbances. We performed a scoping review on this topic, focusing primarily on cognitive manifestations.</AbstractText><AbstractText Label="METHODS">Abstracts and full texts of studies published on PubMed (until May 2023) addressing cognitive involvement persisting after SARS-CoV-2 infection were reviewed, focusing on terms used to name the cognitive syndrome, reported symptoms, their onset time and duration, and testing batteries employed. Reported psychiatric symptoms, their assessment tools, and more general manifestations were also extracted.</AbstractText><AbstractText Label="RESULTS">Among the 947 records identified, 180 studies were included. Only one third of them used a label to define the syndrome. A minority of studies included patients according to stringent temporal criteria of syndrome onset (34%), whereas more studies reported a minimum required symptom duration (77%). The most frequently reported cognitive symptoms were memory and attentional-executive disturbances, and among psychiatric complaints, the most frequent were anxiety symptoms, depression, and sleep disturbances. Most studies reported fatigue among general symptoms. Thirty-six studies employed cognitive measures: screening tests alone (n&#x2009;=&#x2009;19), full neuropsychological batteries (n&#x2009;=&#x2009;25), or both (n&#x2009;=&#x2009;29); 30 studies performed psychiatric testing. Cognitive deficits were demonstrated in 39% of subjects, the most frequently affected domains being attention/executive functions (90%) and memory (67%).</AbstractText><AbstractText Label="CONCLUSIONS">Currently, no agreement exists on a label for post-COVID-19 cognitive syndrome. The time of symptom onset after acute infection and symptom duration are still discussed. Memory and attention-executive complaints and deficits, together with fatigue, anxiety, and depression symptoms, are consistently reported, but the objective evaluation of these symptoms is not standardized.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. European Journal of Neurology published by John Wiley &amp; Sons Ltd on behalf of European Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nicotra</LastName><ForeName>Alessia</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0007-2790-0796</Identifier><AffiliationInfo><Affiliation>Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masserini</LastName><ForeName>Federico</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-0746-7426</Identifier><AffiliationInfo><Affiliation>Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calcaterra</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-7625-1979</Identifier><AffiliationInfo><Affiliation>Unit of Clinical and Experimental Immunology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital, Rozzano, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Vito</LastName><ForeName>Clara</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-7248-1710</Identifier><AffiliationInfo><Affiliation>Unit of Clinical and Experimental Immunology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital, Rozzano, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doneddu</LastName><ForeName>Pietro Emiliano</ForeName><Initials>PE</Initials><Identifier Source="ORCID">0000-0003-4203-6792</Identifier><AffiliationInfo><Affiliation>Neuromuscular and Neuroimmunology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital, Rozzano, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Humanitas University, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pomati</LastName><ForeName>Simone</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-8930-6361</Identifier><AffiliationInfo><Affiliation>Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nobile-Orazio</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-2624-8138</Identifier><AffiliationInfo><Affiliation>Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuromuscular and Neuroimmunology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital, Rozzano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riva</LastName><ForeName>Agostino</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-3171-3049</Identifier><AffiliationInfo><Affiliation>Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mavilio</LastName><ForeName>Domenico</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-6147-0952</Identifier><AffiliationInfo><Affiliation>Unit of Clinical and Experimental Immunology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital, Rozzano, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pantoni</LastName><ForeName>Leonardo</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-7357-8530</Identifier><AffiliationInfo><Affiliation>Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Neurol</MedlineTA><NlmUniqueID>9506311</NlmUniqueID><ISSNLinking>1351-5101</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Eur J Neurol. 2023 Dec;30(12):3640-3641. doi: 10.1111/ene.16082</RefSource><PMID Version="1">37786966</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">cognition</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">neuropsychological</Keyword><Keyword MajorTopicYN="N">post-COVID</Keyword><Keyword MajorTopicYN="N">psychiatric</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>10</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>4</Day><Hour>19</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>4</Day><Hour>17</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37540896</ArticleId><ArticleId IdType="doi">10.1111/ene.16027</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Miskowiak KW, Johnsen S, Sattler SM, et al. Cognitive impairments four months after COVID-19 hospital discharge: pattern, severity and association with illness variables. Eur Neuropsychopharmacol. 2021;46:39-48. doi:10.1016/j.euroneuro.2021.03.019</Citation></Reference><Reference><Citation>Nath A. Neurologic Manifestations of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. 2021. http://journals.lww.com/continuum</Citation></Reference><Reference><Citation>Chen X, Laurent S, Onur OA, et al. A systematic review of neurological symptoms and complications of COVID-19. J Neurol. 2021;268(2):392-402. doi:10.1007/s00415-020-10067-3</Citation></Reference><Reference><Citation>Harapan BN, Yoo HJ. Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19). J Neurol. 2021;268(9):3059-3071. doi:10.1007/s00415-021-10406-y</Citation></Reference><Reference><Citation>Misra S, Kolappa K, Prasad M, et al. Frequency of neurologic manifestations in COVID-19. Neurology. 2021;97(23):E2269-E2281. doi:10.1212/WNL.0000000000012930</Citation></Reference><Reference><Citation>Guedes BF. NeuroCOVID-19: a critical review. Arq Neuropsiquiatr. 2022;80:281-289. doi:10.1590/0004-282X-ANP-2022-S136</Citation></Reference><Reference><Citation>Hayes LD, Ingram J, Sculthorpe NF. More than 100 persistent symptoms of SARS-CoV-2 (long COVID): a scoping review. Front Med (Lausanne). 2021;8:750378. doi:10.3389/fmed.2021.750378</Citation></Reference><Reference><Citation>Heyman A, Garvey S, Herrera-Escobar JP, et al. The impact of the COVID-19 pandemic on functional and mental health outcomes after trauma. Am J Surg. 2022;224(1):584-589. doi:10.1016/j.amjsurg.2022.03.012</Citation></Reference><Reference><Citation>Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ. 2020;370:m3026. doi:10.1136/bmj.m3026</Citation></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22(4):e102-e107. doi:10.1016/S1473-3099(21)00703-9</Citation></Reference><Reference><Citation>Venkatesan P. NICE guideline on long COVID. Lancet Respir Med. 2021;9(2):129. doi:10.1016/S2213-2600(21)00031-X</Citation></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. eClinicalMedicine. 2021;38:101019. doi:10.1016/j.eclinm.2021.101019</Citation></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):89. doi:10.1186/s13643-021-01626-4</Citation></Reference><Reference><Citation>Heming M, Li X, R&#xe4;uber S, et al. Neurological manifestations of COVID-19 feature T cell exhaustion and dedifferentiated monocytes in cerebrospinal fluid. Immunity. 2021;54(1):164-175.e6. doi:10.1016/j.immuni.2020.12.011</Citation></Reference><Reference><Citation>Stefanou MI, Palaiodimou L, Bakola E, et al. Neurological manifestations of long-COVID syndrome: a narrative review. Ther Adv Chronic Dis. 2022;13:20406223221076890. doi:10.1177/20406223221076890</Citation></Reference><Reference><Citation>Premraj L, Kannapadi NV, Briggs J, et al. Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: a meta-analysis. J Neurol Sci. 2022;434:120162. doi:10.1016/j.jns.2022.120162</Citation></Reference><Reference><Citation>Munblit D, Nicholson TR, Needham DM, et al. Studying the post-COVID-19 condition: research challenges, strategies, and importance of Core Outcome Set Development. BMC Med. 2022;20(1):50. doi:10.1186/s12916-021-02222-y</Citation></Reference><Reference><Citation>Hartung TJ, Neumann C, Bahmer T, et al. Fatigue and cognitive impairment after COVID-19: a prospective multicentre study. eClinicalMedicine. 2022;53:101651. doi:10.1016/j.eclinm.2022.101651</Citation></Reference><Reference><Citation>Taquet M, Sillett R, Zhu L, et al. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1&#x2008;284&#x2008;437 patients. Lancet Psychiatry. 2022;9(10):815-827. doi:10.1016/S2215-0366(22)00260-7</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>